Lipoprotein effects of different thiazolidinediones in clinical practice.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Fernando Ovalle, D S Bell

Abstract

To investigate and compare the effects of troglitazone and rosiglitazone on plasma lipoproteins in patients with type 2 diabetes mellitus and dyslipidemia. This cohort study was conducted in the Diabetes Clinic of the University of Alabama. We identified and studied 18 patients with type 2 diabetes and dyslipidemia first treated with troglitazone (600 mg/day) and then transferred to rosiglitazone therapy (8 mg/day). By lowering insulin resistance, thiazolidinediones have common effects on lipoproteins; however, these drugs may have important differences in their effects on individual lipid particles. In our patients, both troglitazone and rosiglitazone increased low-density lipoprotein (LDL) levels; however, only rosiglitazone significantly changed the LDL particle size to the larger, less atherogenic LDL particle. Similarly, both troglitazone and rosiglitazone increased high-density lipoprotein (HDL) concentrations; however, although troglitazone increased only HDL(3), rosiglitazone also significantly increased the larger, more cardioprotective HDL(2) particle. Furthermore, only troglitazone increased Lp(a) significantly. In contrast, rosiglitazone and not troglitazone significantly increased triglycerides. Small but significa...Continue Reading

References

Feb 24, 2001·Annals of Internal Medicine·A A ParulkarV A Fonseca
Aug 11, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·D S BellS Shadmany

❮ Previous
Next ❯

Citations

Mar 29, 2008·Metabolic Syndrome and Related Disorders·David Bell
Sep 29, 2011·Journal of Lipid Research·Aseel AlSalehThomas A B Sanders
Sep 28, 2005·Treatments in Endocrinology·Emily Darby, Bradley D Anawalt
Oct 13, 2005·Diabetes, Obesity & Metabolism·Daniel E RosenbergBarry J Goldstein
Jul 15, 2003·Current Opinion in Cardiology·Daryl A CottrellJames M Falko
Oct 24, 2007·The Journal of Nutrition·Huiyun ShenBernhard Hennig
Aug 18, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·David S H Bell
Sep 15, 2009·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Xunde XianGeorge Liu
May 27, 2004·Diabetes Care·Ronald M Krauss

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
D S Bell, Fernando Ovalle
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
D S BellS Shadmany
© 2022 Meta ULC. All rights reserved